Home › Ziekte van Crohn › Texas › Tyler
Ziekte van Crohn klinische studies in Tyler, TX
16 studies voor Ziekte van Crohn zoeken deelnemers op locaties in en rond Tyler (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RekruterenFase 3
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RekruterenFase 3
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RekruterenFase 2
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
RekruterenFase 3
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RekruterenFase 2/3
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RekruterenFase 2
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RekruterenFase 3
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekruterenFase 3
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekruterenFase 3
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RekruterenFase 2
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RekruterenFase 4
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
RekruterenFase 3
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RekruterenFase 3
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RekruterenFase 2
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
RekruterenFase 2
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RekruterenFase 2
- Mirador Therapeutics Selected Site, Tyler
Ziekte van Crohn studies in andere steden
- New York City, NY35 studies
- Cleveland, OH19 studies
- St. Louis, MO19 studies
- Boston, MA19 studies
- Miami, FL19 studies
- Orlando, FL17 studies
- Houston, TX17 studies
- Atlanta, GA17 studies
- San Diego, CA15 studies
- San Antonio, TX15 studies
- Los Angeles, CA15 studies
- Philadelphia, PA13 studies
Andere studies in Tyler
- Niet-kleincellige longkanker20 studies
- Colitis ulcerosa14 studies
- Colorectale kanker8 studies
- Hartfalen8 studies
- Kanker (alle vormen)7 studies
- Eierstokkanker7 studies
- Endometriumkanker6 studies
- Plaveiselcelcarcinoom van hoofd en hals6 studies
- Borstkanker6 studies
- Metastatische kanker5 studies
- Inflammatoire darmaandoening5 studies
- Chronische lymfatische leukemie5 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.